Locations:
Search
Evolocumab halves cardiovascular events in exploratory analysis
Leading cardiologist picks studies with most impact
Aggressive intervention fails to improve outcomes
Unprecedented LDL-C reductions raise hopes for long-term outcome trials
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Systems will share clinical, academic and research components
A closer look at extended antiplatelet therapy
Further lowering LDL reduces risk in post-ACS patients
20 years, 50 key developments
Veteran surgeon will lead nation’s top cardiac program
From prevention and pacing to stenting and surgery
Advertisement
Advertisement